- March 22, 2018
- Posted by: PharmaScroll
- Category:
Emerald Health Pharmaceuticals Inc. (EHP) announced on March 21st 2018, the published results of a study supporting the potential of its drug candidate, EHP-101 (previously known as VCE-004.8), to treat multiple sclerosis (MS). EHP-101 is a patented derivative of cannabidiol (CBD) modified to affect peroxisome-proliferator activator receptor gamma (PPARg) and cannabinoid receptor 2 (CB2) as well as the hypoxia inducible factor (HIF) pathway. These receptors and physiologic pathways are well documented in multiple peer reviewed publications to be validated targets relating to inflammatory and neurodegenerative processes associated with MS and other neurodegenerative diseases. The study showed that EHP-101 reduced neuroinflammation, prevented demyelination and nerve cell damage, and may enhance remyelination, as suggested by complete recovery of motor activity in an animal model.
These results were published in Journal of Neuroinflammation in a paper entitled, “Hypoxia mimetic activity of VCE-004.8, a cannabidiol quinone derivative: implications for multiple sclerosis therapy.”
“There are no approved drugs capable of reversing MS and very limited treatment options for the more severe and progressive forms of MS. We have observed positive preclinical results with EHP-101, dramatically reversing the debilitating effects of MS in animals,” said Jim DeMesa, MD, CEO of Emerald Health Pharmaceuticals. “Our scientists’ pioneering work provides us the opportunity to advance unique treatment regimens for different stages and forms of MS.”
Researchers evaluated the anti-inflammatory and neuroprotective properties of EHP-101 in two animal models of MS, one reflecting the most common early stage disease, the other representing a more aggressive form of the disease, primary progressive MS. In the model representing early stage disease the clinical manifestations of MS were attenuated in mice receiving EHP-101. In the model mimicking primary progressive MS, mice whose motor activity had declined to very low levels completely recovered to normal levels of motor activity. Assessing demyelination and nerve cell (axonal) damage, which are considered the histopathological hallmarks of MS, demyelination was significantly prevented in EHP-101-treated mice, while intense spinal cord demyelination was found in the untreated control group. Axonal disorganization was prevented by the treatment and the drug inhibited expression of proinflammatory markers.
“Our cannabinoid derivatives are designed to improve bioactivity and therapeutic utility of their natural precursors and it is clear that EHP-101 is achieving mechanistic outcomes that could be an important step for MS science,” said Eduardo Muñoz, PhD, EHP’s Chief Scientific Officer and Professor of Immunology at the University of Córdoba. “Our molecularly-modified CBD derivative modulated neuroinflammation and suggested an ability to enable remyelination based on the complete turnaround of motor activity observed in the animals in this study.”
EHP is currently developing two drug candidates from its portfolio of cannabinoid analogs, one derived from CBD for multiple sclerosis and scleroderma, EHP-101, and one derived from cannabigerol (CBG), EHP-102, for Huntington’s disease and Parkinson’s disease. Additional data were previously published in two papers in the journal Scientific Reports, a Nature publication, as well as Journal of Neuroinflammation. EHP plans to start a human study in H2 2018 for multiple sclerosis and scleroderma, and expects to begin clinical-enabling studies for Parkinson’s disease and Huntington’s disease by 2019.
About Pharmascroll:
Pharmascroll is a diligent business consulting and market research firm focused solely towards pharmaceutical markets. The company consults and researches in majorly chronic disease indications prevalent across the globe. The research conducted by Pharmascroll analysts is targeted to provide analytical and logical answers to the key business questions of the pharmaceutical and medical insights teams and to make better informed business decisions with the detailed relevant information available.
To read more news about Multiple Sclerosis, visit https://pharmascroll.com/news-category/multiple-sclerosis/
News Source: www.emeraldpharma.life
Image Source: https://www.unforgettable.org/blog/scientists-say-alzheimers-drug-may-stop-the-disease-from-ever-developing/